Navigation Links
Amicus Therapeutics Announces First Quarter 2008 Financial Results
Date:5/13/2008

tors presented positive results from Phase 2 clinical trials of Amigal at the American College of Medical Genetics (ACMG) meeting. The data showed that Amigal was generally safe and well-tolerated at all doses evaluated and no drug-related serious adverse events were reported. In addition, Amigal increased the level of the enzyme deficient in Fabry patients in 24 of 26 study subjects, and in a majority of study subjects the treatment resulted in a reduction of kidney GL-3 as measured in urine.

Amicus, along with its partner Shire, has initiated discussions with the U. S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) regarding its plans for Phase 3 clinical evaluation of Amigal. Amicus expects to complete these interactions and provide an update in the second half of 2008, and subject to the outcome of the discussions, the Company plans to initiate the Phase 3 clinical trial in the first half of 2009.

In parallel with the regulatory process, 23 of the original 26 patients continue to be treated with Amigal in the voluntary Phase 2 extension study to monitor long term safety and efficacy. In addition, the Company will evaluate modified doses and dose regimens in these 23 patients. Data from this extension study are expected to be available by Q1 2009, prior to finalization of the Phase 3 protocol.

Gaucher Disease:

Plicera(TM) (isofagomine tartrate) is an investigational, oral therapeutic being developed for the treatment of Gaucher disease. At the ACMG meeting in March, clinical investigators presented full data from a 4 week Phase 2 study in Gaucher patients who switched from enzyme replacement therapy (ERT) with imiglucerase to the pharmacological chaperone Plicera. Results showed that Plicera was generally safe and well tolerated at all doses and increased target enzyme activity levels in a majority of patients. In the trial, GCase activity, as measured in white blood cells, was increased in 20 of the 26 pat
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/z54c4k/biomedical ) has ... and Freezers Market - Global Industry Analysis, Size, ... report to their offering. ... been segmented based on applications: hospitals, research laboratories, ... others segment includes applications of biomedical refrigerators and ...
(Date:7/28/2015)... , July 28, 2015  Kerastem Technologies announce that ... the U.S. FDA Center For Biologics Evaluation and Research ... conduct a clinical trial investigating the safety and feasibility ... and early male pattern baldness (androgenic alopecia). ... follows initial clinical work in Europe ...
(Date:7/28/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS ... granted to German life sciences entrepreneurs with a ... of biotechnology (collectively, the "Optionee"), an option to ... vaccine technology (the "Technology"), including AEZS-120, the most ... ready to enter a Phase 1 clinical trial. ...
(Date:7/27/2015)... , July 27, 2015  Amgen (NASDAQ: AMGN ... quarter financial results on Thursday, July 30, 2015, after ... will be followed by a conference call with the ... call from Amgen will be Robert A. Bradway ... of Amgen,s senior management team. Live audio ...
Breaking Biology Technology:Biomedical Refrigerators and Freezers Market Report - Global Industry Analysis 2015 2Biomedical Refrigerators and Freezers Market Report - Global Industry Analysis 2015 3Kerastem Receives Conditional Approval from FDA for Alopecia Trial 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 3Amgen Announces Webcast of 2015 Second Quarter Financial Results 2
... , In a study to be published in the April ... University,s School of Engineering and Applied Science report their findings ... Pole, has affected the entire circulation of the Southern Hemisphere ... shown that the ozone hole is changing the atmospheric flow ...
... April 21, 2011 KellBenx, a biotechnology company focused ... genetic and inherited disorders, announced today that it has ... four investors –  three biotechnology venture capital groups and ... trial and laboratory testing of a new, minimally invasive ...
... University of California, Riverside,s Bourns College of Engineering ... work in nanotechnology that could have far-reaching impacts ... of electrical engineering and founding chair of a ... to receive the Pioneer of Nanotechnology Award for ...
Cached Biology Technology:Columbia engineering study links ozone hole to climate change all the way to the equator 2Columbia engineering study links ozone hole to climate change all the way to the equator 3Engineering professor wins award for pioneering work expected to improve electronic devices 2
(Date:7/27/2015)... July 27, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced that Huawei has selected the ... for its stylish smartwatch. Huawei chose the state-of-the-art ... low power and highly responsive human interface qualities ... designers also required a classic round watch face ...
(Date:7/27/2015)... LOS ANGELES , July 27, 2015 /PRNewswire/ ... providing evidence- and experience-based clinical improvement solutions, today ... coordination solution is now available on Android smartphones ... at inpatient and post-care organizations can use ZynxCarebook ... the same patient,s condition, streamline care transitions to ...
(Date:7/23/2015)... Inc. (NASDAQ: AWRE ), a leading supplier of biometrics ... quarter ended June 30, 2015.  Revenue for ... of 33% compared to $6.8 million in the same quarter ... was $0.3 million, or $0.01 per diluted share, which compared ... same period a year ago.  Lower revenue ...
Breaking Biology News(10 mins):Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6
... alumnus) Hudi Benayahu, head of TAU,s Porter School of ... and important part of reef environments, are simply melting ... mean a global marine catastrophe. Environmental stress, says ... and the microscopic symbiotic algae living in their tissues. ...
... vaccine be the key to stopping Alzheimers disease" A ... (OMRF) shows that immunization could offer a way to ... OMRF scientists immunized Alzheimers mice with a protein believed ... The mice who received the vaccination showed a significant ...
... the European Molecular Biology Laboratory [EMBL] announces Luxembourg ... Accepted by EMBL,s council and ratified by the ... the institute as the 20th member state. ... biology," says Franois Biltgen, Minister of Culture, Higher ...
Cached Biology News:TAU professor finds global warming is melting soft coral 2An Alzheimer's vaccine? 2An Alzheimer's vaccine? 3Luxembourg joins EMBL 2
... Anti-Clusterin α chain (human), clone 41D ... Immunogen : Native clusterin purified ... pH 7.4, 0.15M NaCl and 0.05% ... on RIPA lysates from HeLa cells ...
Rabbit polyclonal to Methionine Aminopeptidase 2 ( Abpromise for all tested applications). entrezGeneID: 10988 SwissProtID: P50579...
Chlamydia pneumoniae (TWAR)...
Mouse anti-Insulin-Like-3 Class: Antibody Product Group: Adipokine and Obesity related...
Biology Products: